G1 Therapeutics, Inc.

G1 Therapeutics, Inc.verified

GTHX

Price:

$3.63

Market Cap:

$189.78M

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical ...[Read more]

Industry

Biotechnology

IPO Date

2017-05-17

Stock Exchange

NASDAQ

Ticker

GTHX

The PE Ratio as of July 2024 (TTM) for G1 Therapeutics, Inc. (GTHX) is -6.05

According to G1 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.05. This represents a change of 257.34% compared to the average of -1.69 of the last 4 quarters.

G1 Therapeutics, Inc. (GTHX) Historical PE Ratio (quarterly & annually)

How has GTHX PE Ratio performed in the past?

The mean historical PE Ratio of G1 Therapeutics, Inc. over the last ten years is -6.41. The current -6.05 PE Ratio has changed 9.35% with respect to the historical average. Over the past ten years (40 quarters), GTHX's PE Ratio was at its highest in in the June 2023 quarter at 3.69. The PE Ratio was at its lowest in in the September 2018 quarter at -21.80.

Quarterly (TTM)
Annual

Average

-6.41

Median

-6.44

Minimum

-15.12

Maximum

-1.61

G1 Therapeutics, Inc. (GTHX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of G1 Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 489.89%

Maximum Annual PE Ratio = -1.61

Minimum Annual Increase = -57.95%

Minimum Annual PE Ratio = -15.12

Quarterly (TTM)
Annual
YearPE RatioChange
2023-3.29104.90%
2022-1.61-44.39%
2021-2.89-57.95%
2020-6.87-15.43%
2019-8.128.52%
2018-7.4824.57%
2017-6.01-40.64%
2016-10.12-33.11%
2015-15.12489.89%

G1 Therapeutics, Inc. (GTHX) Average PE Ratio

How has GTHX PE Ratio performed in the past?

The current PE Ratio of G1 Therapeutics, Inc. (GTHX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.59

5-year avg

-4.55

10-year avg

-6.41

G1 Therapeutics, Inc. (GTHX) PE Ratio vs. Peers

How is GTHX’s PE Ratio compared to its peers?

G1 Therapeutics, Inc.’s PE Ratio is less than Allogene Therapeutics, Inc. (-1.65), greater than Heron Therapeutics, Inc. (-6.07), less than Annexon, Inc. (-5.72), less than Sangamo Therapeutics, Inc. (-0.22), less than X4 Pharmaceuticals, Inc. (-1.18), greater than HOOKIPA Pharma Inc. (-16.94), greater than Mereo BioPharma Group plc (-77.28), less than Galera Therapeutics, Inc. (-0.15), less than Acumen Pharmaceuticals, Inc. (-3.07), greater than Atara Biotherapeutics, Inc. (-6.64), less than Fate Therapeutics, Inc. (-2.27), less than Sana Biotechnology, Inc. (-4.08), less than Caribou Biosciences, Inc. (-1.78), less than Arcus Biosciences, Inc. (-5.33), greater than Day One Biopharmaceuticals, Inc. (-6.21), greater than Blueprint Medicines Corporation (-24.56), greater than Axsome Therapeutics, Inc. (-13.57), less than PDS Biotechnology Corporation (-3.07), less than Amylyx Pharmaceuticals, Inc. (-1.93), less than Coherus BioSciences, Inc. (-3.12), greater than Larimar Therapeutics, Inc. (-11.07), less than Puma Biotechnology, Inc. (11.47), greater than MacroGenics, Inc. (-13.19),

Build a custom stock screener for G1 Therapeutics, Inc. (GTHX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like G1 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

G1 Therapeutics, Inc. (GTHX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like G1 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is G1 Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for G1 Therapeutics, Inc. (GTHX)?

What is the highest PE Ratio for G1 Therapeutics, Inc. (GTHX)?

What is the 3-year average PE Ratio for G1 Therapeutics, Inc. (GTHX)?

What is the 5-year average PE Ratio for G1 Therapeutics, Inc. (GTHX)?

How does the current PE Ratio for G1 Therapeutics, Inc. (GTHX) compare to its historical average?